BioCardia pauses PhIII enrollment in trial of heart failure stem cell therapy

BioCardia has paused enrollment in a pivotal study of its stem cell therapy for heart failure after an independent review board determined the trial was not likely to succeed.

The Sunnyvale, CA-based biotech said Monday morning that the data and safety monitoring board (DSMB) reviewed an…
Click here to view original post